AstraZeneca's Investigational Hypertension Drug Baxdrostat Achieves Primary Endpoint in Late-Stage Trial

Gelonghui October 7 | According to Yicai, AstraZeneca stated on October 7 that its investigational hypertension drug baxdrostat achieved the primary goal in a late-stage clinical trial targeting patients with resistant hypertension, significantly reducing blood pressure. AstraZeneca plans to submit baxdrostat for regulatory approval by the end of the year and expects the drug's annual sales to exceed $5 billion at its peak. Other indications currently under clinical investigation for this drug include chronic kidney disease and heart failure prevention.